BioNTech and Genentech terminated a Phase 2 program for their personalized mRNA cancer vaccine after outcomes failed to match control benchmarks and the trial was described as recording more deaths in the investigational group. The decision arrives shortly after competing personalized mRNA approaches reported major success in different cancer settings. The scrapped Phase 2 effort underscores the difficulty of translating individualized vaccine concepts into consistent clinical benefit, particularly when trial performance relies on both immunogenicity and durable outcomes. BioNTech’s cancellation also highlights the rapid reassessment of development programs following readouts. For investors and pipeline teams, the move increases scrutiny on endpoints, patient selection, and the durability of anti-tumor immune responses in individualized mRNA designs.